EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In vitro and in vivo activity of quisinostat against Toxoplasma gondii

Hui-Jie Qiu, Wen-Bin Zheng iD, Ting Zeng, Shu-Feng Yang, Dai-Ang Liu, Li-Yan Wang, Zhi-Rong Liu, Xing-Quan Zhu iD, Chun-Xue Zhou iD

Antimicrobial Agents and Chemotherapy · 2025

DOI: 10.1128/aac.01819-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Hui-Jie Qiu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Parasitic Diseases, College of Veterinary Medicine, Shanxi Agricultural University, Taigu, Shanxi, China. Hauptthemen laut MEDLINE: Toxoplasma, Antiprotozoal Agents, Toxoplasmosis, Hydroxamic Acids. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Toxoplasma gondii, an opportunistic pathogen, poses severe threats to immunocompromised individuals and fetuses of newly infected pregnant women. The current gold-standard treatment, a combination of pyrimethamine and sulfadiazine, is limited by severe adverse events, necessitating the development of novel therapeutic agents. In vitro , a CCK8 assay demonstrated that quisinostat inhibited HeLa cell proliferation in a dose-dependent manner, with a CC 50 of 8.22 nM. Regarding T. gondii tachyzoites, quisinostat exhibited time-dependent inhibition of extracellular parasite activity and suppressed intracellular parasite proliferation, with an EC 50 of 25.84 pM, and a high selectivity index (SI = 318.11). Quisinostat disrupted the T. gondii lytic cycle by decreasing invasion rates, inducing G1 cell cycle arrest, reducing replication, and shrinking plaque size. Ultrastructural analysis indicated that quisinostat treatment led to membrane damage, enhanced lactate dehydrogenase (LDH) release, and apoptotic cell death in tachyzoites, whereas no significant change in reactive oxygen species (ROS) levels was detected. Proteome analysis identified 77 upregulated and 205 downregulated proteins, which were enriched in functions associated with protein dephosphorylation and ion transport, as well as pathways, such as non-homologous end-joining. Molecular docking studies revealed a strong interaction between quisinostat and T. gondii HDAC3. In vivo , treatment with quisinostat increased the survival time of mice infected with virulent RH strain. In mice infected with low-virulent ME49 tachyzoites, quisinostat treatment decreased parasite burden in multiple organs and increased the survival to 80%. Taken together, these findings demonstrate that quisinostat has potent anti- Toxoplasma activity both in vitro and in vivo , which offers promise for treatment of human toxoplasmosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ToxoplasmaAntiprotozoal AgentsToxoplasmosisHydroxamic AcidsAnimalsHumansMiceHeLa CellsFemaleReactive Oxygen SpeciesMice, Inbred BALB CApoptosisCell Proliferation

Stichwörter der Autor:innen

EC50Toxoplasma gondiimouseproteomequisinostat

Substanzen

Reactive Oxygen SpeciesAntiprotozoal AgentsHydroxamic Acids

Autor:innen und Institutionen

  • Laboratory of Parasitic Diseases, College of Veterinary Medicine, Shanxi Agricultural University, Taigu, Shanxi, China.
  • Department of Pathogen Biology, School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
  • Shandong Public Health Clinical Center, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
  • National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention (Chinese Center for Tropical Diseases Research), NHC Key Laboratory of Parasite and Vector Biology, WHO Collaborating Center fo…

ORCID-Profile: Wen-Bin Zheng, Xing-Quan Zhu, Chun-Xue Zhou

Zitieren

APA

Qiu, H. J., Zheng, W. B., Zeng, T., Yang, S. F., Liu, D. A., Wang, L. Y., Liu, Z. R., Zhu, X. Q., & Zhou, C. X. (2025). In vitro and in vivo activity of quisinostat against Toxoplasma gondii. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01819-24

Vancouver

Qiu HJ, Zheng WB, Zeng T, Yang SF, Liu DA, Wang LY, et al. In vitro and in vivo activity of quisinostat against Toxoplasma gondii. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.01819-24

BibTeX
@article{Qiu2025,
  author = {Qiu, Hui-Jie and Zheng, Wen-Bin and Zeng, Ting and Yang, Shu-Feng and Liu, Dai-Ang and Wang, Li-Yan and Liu, Zhi-Rong and Zhu, Xing-Quan and Zhou, Chun-Xue},
  title = {In vitro and in vivo activity of quisinostat against Toxoplasma gondii},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2025},
  doi = {10.1128/aac.01819-24}
}
Kostenlos starten →